Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programs

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the expansion of its leadership team with the appointment of Patti Connolly as vice president of clinical and scientific affairs and Paul Brenner, Ph.D. to the Advisory Board. 

As vice president of clinical and scientific affairs, Connolly is leading RenalytixAI's recruitment efforts for the prospective clinical utility study for its lead diagnostic, KidneyIntelX, which is scheduled to start in Q4 2019.

Connolly brings more than two decades of leadership experience in clinical research and development, the past ten years of which have focused on managing successful clinical trials as well as domestic and international regulatory affairs initiatives. Most recently, Connolly served as clinical services director at Pearl Pathways where she was responsible for all clinical services operations, the full-service contract research organization and the institutional review board. Connolly received a bachelor's degree in Microbiology, and a master's degree in Pathology and Laboratory Medicine from Indiana University.

RenalytixAI also announced the addition of Brenner, a computer science faculty member at the University of Notre Dame and Associate Director of Notre Dame's Center for Research Computing, to its Advisory Board. Brenner contributes deep expertise in advanced computation, artificial intelligence and cyber security to the RenalytixAI Advisory Board. In his role at the University of Notre Dame, Brenner advances computation-based research through cyber system security, design, deployment and operation, and directs a team of technical experts in the operation of high-performance computing hardware and software infrastructure for an active user base of over 2,000 researchers. Brenner also serves as a Senior Reserve Advisor to the Air Force Cyber College Commandant (AFCC). In this capacity he advises the AFCC leadership on military reserve matters and leads the provision of technical and operational capabilities to AFCC. Brenner received his bachelor's degree in Civil Engineering from the University of Notre Dame, a master's in Materials Science and Engineering from Ohio State University, and a doctoral degree in Computer Science and Engineering from University of Notre Dame.                                          

About RenalytixAI RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

SOURCE RenalytixAI